India Cuts Cancer Drug Prices From November 9, Aiming to Slash Patient Costs

India’s National Pharmaceutical Pricing Authority (NPPA) announced that the prices of several anti‑cancer drugs will be reduced from November 9, a move designed to curb the steep out‑of‑pocket costs that many patients face during treatment. The revision targets key medicines that are often the biggest line item on a cancer patient’s bill.

The country’s cancer burden is staggering: in 2025, the Observer Research Foundation estimated about 1.56 million new cases and 902,000 deaths, making India the second‑most affected Asian nation after China. Compared with neighbours, Indonesia recorded 474,000 cases and 283,000 deaths, while Pakistan had 190,000 cases and 120,000 deaths; Bangladesh, Thailand, Sri Lanka, and Nepal reported far lower numbers.

Lung cancer remains the deadliest in India, with roughly 98,700 deaths, followed closely by breast cancer at 96,100. Oral cavity cancers claimed 86,300 lives, oesophageal cancer 73,000 and stomach cancer 45,000. Liver, colorectal, cervical, blood, and ovarian cancers also contribute significantly to the mortality tally.

Despite the high incidence, India’s cancer case‑fatality rate sits at 57.8 %, lower than most regional peers—Bangladesh (74.3 %), Nepal (70.8 %), Thailand (65.5 %), Pakistan (63.2 %), Sri Lanka (62.8 %) and Indonesia (59.7 %). China leads with 50.1 %, indicating that Indian patients generally have better survival odds once diagnosed.

The NPPA’s price cuts could ease a major barrier to treatment: affordability. By making drugs cheaper, the move may expand access to standard care, reduce financial strain on families, and ultimately improve outcomes for cancer patients across the country. Patients and clinicians should monitor how these changes affect drug availability and consider them when planning treatment strategies.